Series: Landmark Trials in Endocrinology & Metabolism | Study #13
Category: GLP-1 Receptor Agonists · Obesity · Cardiovascular Outcomes | Design: Multicentre, double-blind, placebo-controlled, event-driven RCT | n: 17,604 | Follow-up: 39.8 months (median)
📋 Summary
Authors: Lincoff AM et al., for the SELECT Trial Investigators
Journal: N Engl J Med 2023;389:2221–2232 | DOI: 10.1056/NEJMoa2307563
SELECT enrolled 17,604 adults aged 45 years or older with pre-existing cardiovascular disease, a BMI of 27 or more, and no type 2 diabetes mellitus at baseline. Participants were randomly assigned to semaglutide 2.4 mg once weekly or placebo for a median follow-up of 39.8 months. The primary endpoint was first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE). The primary endpoint occurred in 6.5% of participants in the semaglutide group and 8.0% in the placebo group (HR 0.80; 95% CI 0.72 to 0.90; p<0.001), a 20% relative risk reduction. Among the individual components, nonfatal MI was significantly reduced (HR 0.72; 95% CI 0.61 to 0.87). Cardiovascular death (HR 0.85; 95% CI 0.71 to 1.01) and nonfatal stroke (HR 0.82; 95% CI 0.61 to 1.10) did not reach individual statistical significance. Mean body weight at baseline was 96.2 kg (mean BMI 33.4 kg/m²); semaglutide produced a mean weight reduction of 9.4% versus 0.9% with placebo at 104 weeks. SELECT was the first dedicated cardiovascular outcomes trial designed for an obesity pharmacotherapy agent in a non-diabetic population, and the first to demonstrate that weight-loss pharmacotherapy can reduce hard cardiovascular events.
📊 Key Findings
| Outcome | Semaglutide 2.4 mg | Placebo | Effect Size |
|---|---|---|---|
| 3-point MACE (CV death, MI, stroke) | 6.5% | 8.0% | HR 0.80 (0.72–0.90) · p<0.001 · 20% RRR |
| Nonfatal MI | — | — | HR 0.72 (0.61–0.87) |
| Cardiovascular death | — | — | HR 0.85 (0.71–1.01) · NS |
| Nonfatal stroke | — | — | HR 0.82 (0.61–1.10) · NS |
| Body weight change at 104 weeks | −9.4% | −0.9% | Difference −8.5% |
| Absolute risk reduction (MACE) | ~1.5% over 39.8 months | NNT approximately 67 | |
💬 Expert Commentary
SELECT is a landmark trial not merely within the GLP-1 receptor agonist literature but in the broader field of cardiovascular and metabolic medicine. It provided the first prospective randomised evidence that a pharmacological weight-loss intervention reduces major adverse cardiovascular events. Prior to SELECT, the hypothesis that weight loss per se reduces cardiovascular events had been challenged, most notably by the Look AHEAD trial (Study #15 in this series), which demonstrated that intensive lifestyle-induced weight loss did not reduce MACE in overweight patients with type 2 diabetes over nearly a decade of follow-up. SELECT’s positive result does not contradict Look AHEAD, because the populations were different (no diabetes in SELECT, established CVD required), the degree of weight loss was greater with semaglutide, and the drug may have direct cardiovascular effects mediated through GLP-1 receptor signalling that go beyond weight reduction.
The 20% reduction in MACE driven significantly by a 28% reduction in nonfatal MI is consistent with an anti-atherosclerotic mechanism for semaglutide. This aligns with the component analysis from LEADER and SUSTAIN-6, and with the broader class signal from GLP-1 receptor agonist CVOTs. The contribution of weight loss versus direct receptor-mediated effects to the cardiovascular benefit is difficult to disentangle from the trial data alone, but mediation analyses suggest that weight loss accounts for a minority of the MACE reduction, with receptor-mediated effects on inflammation, endothelial function, and plaque biology likely contributing substantially. SELECT expanded the licensed indication for semaglutide 2.4 mg to include cardiovascular risk reduction in non-diabetic overweight or obese adults with established cardiovascular disease, and it has driven a fundamental reassessment of obesity as a cardiovascular risk condition requiring treatment beyond lifestyle intervention alone.
Limitations: Cardiovascular death and nonfatal stroke were not individually reduced at statistical significance. The population required pre-existing CVD, and SELECT does not address cardiovascular outcomes in lower-risk obese patients. The NNT of 67 over 39.8 months reflects the moderate absolute event rate in the study population. The study was industry-sponsored by Novo Nordisk.
🔑 BOTTOM LINE
SELECT demonstrated that semaglutide 2.4 mg reduces 3-point MACE by 20% in overweight or obese adults with pre-existing cardiovascular disease and no diabetes, becoming the first obesity pharmacotherapy trial to demonstrate hard cardiovascular endpoint reduction and establishing semaglutide as a cardiovascular drug for non-diabetic obesity with established CVD.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
Next in the series: Study #14 SCALE: Liraglutide 3.0 mg for Chronic Weight Management in Obesity
